Medicaid prescription drug policies and medication access and continuity: Findings from ten states

Psychiatric Services

Volumn 60, Issue 5, 2009, Pages 601-610

  West, Joyce C ^a   Wilk, Joshua E ^c   Rae, Donald S ^a   Muszynski, Irvin S ^b   Stipec, Maritza Rubio ^a   Alter, Carol L ^d   Sanders, Karen E ^b   Crystal, Stephen ^e   Regier, Darrel A ^a  

^a Education Psychiatric Practice Research Network   (United States)

^b AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEDATIVE AGENT;

ADULT; ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG INDICATION; DRUG PREFERENCE; DRUG UTILIZATION; EMERGENCY CARE; FEMALE; FINANCIAL MANAGEMENT; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE POLICY; HOMELESSNESS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL PATIENT; PRESCRIPTION; PSYCHIATRIST; SLEEP DISORDER; SOCIAL ASPECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT RESPONSE;

EID: 66249119021     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.5.601     Document Type: Article

References (41)

1. Mark TL, Coffey RM, McKusick DR, et al: National Estimates of Expenditures for Mental Health Services and Substance Abuse Treatment, 1991-2001. Pub no SMA 05-3999. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2005
2. Mark TL, Levit K, Buck J, et al: Mental health treatment expenditure trends, 1986-2003. Psychiatric Services 58:1041-1048, 2007
3. Kaiser Commission on Medicaid and the Uninsured: Medicaid: a Primer. Washington, DC, Kaiser Family Foundation, March 2007. Available at www.kff.org/Medicaid
4. Catlin A, Cowan C, Heffler S, et al: National health spending in 2005: the slowdown continues. Health Affairs 26:142-153, 2007
5. Crowley JS, Ashner D, Elam L: State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update. Washington, DC, Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured, Oct 2005. Available at www. kff.org/medicaid/7381.cfm
6. Fischer MA, Schneeweiss S, Avorn J, et al: Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. New England Journal of Medicine 351:2187-2194, 2004
7. Smalley WE, Griffin MR, Fought RL, et al: Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. New England Journal of Medicine 332:1612-1617, 1995
8. Motheral BR, Henderson R, Cox ER: Plansponsor savings and member experience with point-of-service prescription step therapy. American Journal of Managed Care 10(7 pt 1):457-464, 2004
9. Soumerai SB: Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs 23:135-146, 2004
10. Soumerai SB, Zhang F, Ross-Degan D, et al: Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 27:w185-w195, 2008
11. West JC, Wilk JE, Muszynski IL, et al: Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. American Journal of Psychiatry 164:789-796, 2007
12. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007
13. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of a limit on Medicaid drugreimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331:650-655, 1994
14. Tamblyn R, Laprise R, Hanley JA, et al: Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285:421-429, 2001
15. Koyanagi C, Forquer S, Alfano E: Medicaid policies to contain psychiatric drug costs. Health Affairs 24:536-544, 2005
16. Polinski JM, Wang PS, Fischer MA: Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs 26:750-760, 2007
17. West JC, Wilk J, Olfson M, et al: Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatric Services 56:283-291, 2005
18. West JC, Duffy FF, Wilk J, et al: Patterns and quality of treatment for patients with major depressive disorder in routine psychiatric practice. Focus 3:43-50, 2005
19. Wang PS, Simon GE, Avorn J, et al: Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA 298: 1401-1411, 2007
20. Cunningham PJ: Medicaid cost containment and access to prescription drugs. Health Affairs 24:780-789, 2005
21. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
22. Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52: 805-811, 2001
23. Zygmunt A, Olfson M, Boyer CA, et al: Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159:1653-1664, 2002
24. Robinson D, Woerner MG, Alvir JM, et al: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56:241-247, 1999
25. Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630-639, 2002
26. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161:692-699, 2004
27. Essock SM, Covell NH, Davis SM, et al: Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 163:2090-2095, 2006
28. Wilk JE, West JC, Rae DS, et al: Medicare Part D prescription drug benefits and administrative burden in care of dually eligible psychiatric patients. Psychiatric Services 59:34-39, 2008
29. Gencarelli DM: Medicaid prescription drug coverage: state efforts to control costs. National Health Policy Forum Issue Brief 790:1-17, 2003
30. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Compendium. Arlington, Va, American Psychiatric Association, 2006
31. Kashner TM, Rush AJ, Crismon ML, et al: An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. Psychiatric Services 57:648-659, 2006
32. Sachs GS, Nierenberg AA, Calabrese JR, et al: Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 356:1711-1722, 2007
33. Rush AJ, Trivedi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163:1905-1917, 2006
34. March JS, Silva SG, Compton S, et al: The case for practical clinical trials in psychiatry. American Journal of Psychiatry 162:836-846, 2005
35. Swartz MS, Perkins DO, Stroup TS, et al: Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophrenia Bulletin 29:33-43, 2003
36. Crystal S, Akincigil A, Bilder S, et al: Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Medical Care 45:S58-S65, 2007
37. Piette, JD, Heisler M: Problems due to medication costs among VA and non-VA patients with chronic illnesses. American Journal of Managed Care 10:861-868, 2004
38. Phillips SD, Burns BJ, Edgar ER, et al: Moving assertive community treatment into standard practice. Psychiatric Services 52:771-779, 2001
39. Coldwell CM, Bender WS: The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. American Journal of Psychiatry 164:393-399, 2007
40. Foote SM: Population-based disease management under fee-for-service Medicare. Health Affairs Web Exclusives W3:342-356, July 30, 2003
41. Osterberg L, Blaschke T: Adherence to medication. New England Journal of Medicine 353:487-497, 2005